Sagimet Biosciences (SGMT) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free SGMT Stock Alerts $4.06 +0.14 (+3.57%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024globenewswire.com - April 22 at 8:00 AMSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Buy" from Analystsamericanbankingnews.com - April 21 at 2:12 AMShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Expands By 31.3%marketbeat.com - April 13 at 8:12 PMDavid Happel Buys 12,100 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) Stockinsidertrades.com - March 29 at 8:56 AMLeerink Partnrs Equities Analysts Boost Earnings Estimates for Sagimet Biosciences Inc. (NASDAQ:SGMT)marketbeat.com - March 29 at 8:15 AMSagimet Biosciences Inc. (NASDAQ:SGMT) CEO David Happel Acquires 12,100 Sharesmarketbeat.com - March 28 at 7:55 PMSagimet Biosciences Inc (SGMT) Reports Full Year 2023 Financial Results: A Close Lookfinance.yahoo.com - March 28 at 7:42 PMSagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstatglobenewswire.com - March 27 at 4:01 PMThe Goldman Sachs Group Trims Sagimet Biosciences (NASDAQ:SGMT) Target Price to $27.00marketbeat.com - March 26 at 2:30 PMStrong Buy Recommendation: Sagimet Biosciences’ Unique NASH Drug and Solid Financials Signal Market Growth Potentialmarkets.businessinsider.com - March 25 at 11:30 PMSagimet Biosciences: Strong Buy on Robust Financials and Promising NASH Drug Trialsmarkets.businessinsider.com - March 25 at 11:30 PMSagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-linemsn.com - March 25 at 8:27 AMSVB Leerink Initiates Coverage on Sagimet Biosciences (NASDAQ:SGMT)marketbeat.com - March 25 at 8:09 AMSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directorsglobenewswire.com - March 25 at 7:00 AMSagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updatesglobenewswire.com - March 25 at 6:15 AMRTW Investments LP Invests $3.52 Million in Sagimet Biosciences Inc. (NASDAQ:SGMT)marketbeat.com - March 6 at 11:01 AM738,355 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Rock Springs Capital Management LPmarketbeat.com - March 5 at 7:35 PMShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 44.4%marketbeat.com - March 3 at 7:58 PMSagimet Biosciences to Participate in Two Upcoming Investor Conferencesglobenewswire.com - February 29 at 8:00 AMSagimet Biosciences Stock (NASDAQ:SGMT) Dividends: History, Yield and Datesbenzinga.com - February 25 at 8:48 PMSagimet Biosciences (SGMT) Price Target Increased by 17.19% to 51.00msn.com - February 24 at 7:46 AMPainful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered lossesfinance.yahoo.com - February 23 at 5:53 AM100,000 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Silverarc Capital Management LLCmarketbeat.com - February 18 at 12:54 PMSagimet Biosciences Inc Class A Shares SGMTmorningstar.com - February 17 at 10:25 AMSagimet Biosciences (NASDAQ:SGMT) PT Lowered to $46.00marketbeat.com - February 7 at 11:35 AMBuy Rating Affirmed for Sagimet Biosciences as Phase 2b Results of Denifanstat Outshine Competitorsmarkets.businessinsider.com - February 7 at 12:22 AMSagimet Biosciences price target lowered by $1 at JMP Securities, here's whyrealmoney.thestreet.com - February 6 at 7:21 PMSteven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences Incfinance.yahoo.com - February 6 at 2:21 PMSagimet Biosciences Announces Interim CFO Appointmentmsn.com - February 3 at 11:16 AMSagimet Biosciences Inc. (SGMT)uk.finance.yahoo.com - January 30 at 11:43 PMSagimet Biosciences prices public offering of 9M shares at $12.50 per sharemsn.com - January 26 at 10:35 AMSagimet Biosciences Announces Pricing of Public Offering of Series A Common Stockfinance.yahoo.com - January 26 at 10:35 AMSagimet Biosciences Announces Proposed Public Offering of Series A Common Stockmarkets.businessinsider.com - January 23 at 10:07 PMSagimet Biosciences Announces Proposed Public Offering of Series A Common Stockfinance.yahoo.com - January 23 at 10:07 PMSagimet Biosciences (NASDAQ:SGMT) Given New $37.00 Price Target at The Goldman Sachs Groupmarketbeat.com - January 23 at 10:39 AMSagimet Biosciences price target raised to $47 from $31 at JMP Securitiesrealmoney.thestreet.com - January 22 at 11:12 PMSagimet Biosciences Stock (NASDAQ:SGMT): Don’t Get Squeezed Out of Your Moneymsn.com - January 22 at 11:12 PMJMP Securities Boosts Sagimet Biosciences (NASDAQ:SGMT) Price Target to $47.00marketbeat.com - January 22 at 3:58 PMSagimet Biosciences Shares Rise Premarket on NASH Study Resultsmarketwatch.com - January 22 at 1:11 PMSagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHmarkets.businessinsider.com - January 22 at 1:11 PMSagimet Biosciences Reports Positive Topline Results From Phase 2b FASCINATE-2 Study Of Denifanstatmarkets.businessinsider.com - January 22 at 1:11 PMSagimet Bio surges after mid-stage win for NASH drugmsn.com - January 22 at 1:11 PMWhy Is Fatty Liver Disease Focused Sagimet Biosciences Stock Shooting Higher Today?msn.com - January 22 at 1:11 PMmarketbeat.com - January 22 at 9:51 AMmarketbeat.com - January 22 at 9:42 AMSagimet's fatty liver disease drug shows promise in trialreuters.com - January 22 at 8:10 AMSagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHfinance.yahoo.com - January 22 at 8:10 AMPlatinum Investment Management Ltd. Makes New $3.38 Million Investment in Sagimet Biosciences Inc. (NASDAQ:SGMT)marketbeat.com - January 21 at 9:42 AMSagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - January 13 at 12:19 PMSagimet Biosciences Inc.'s Lock-Up Period Set To End on January 10th (NASDAQ:SGMT)marketbeat.com - January 3 at 1:27 AM Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. SGMT Media Mentions By Week SGMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼0.670.32▲Average Medical News Sentiment SGMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼21▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Karyopharm Therapeutics News Today Vistagen Therapeutics News Today Coya Therapeutics News Today Amylyx Pharmaceuticals News Today InterCure News Today PDS Biotechnology News Today Citius Pharmaceuticals News Today Repare Therapeutics News Today Societal CDMO News Today Nuvectis Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
